What question did this study set out to answer?

The review aims to outline the critical decisions made during the development of the TAK-003 dengue vaccine.

February 5, 2026npj Vaccines3 citationsOpen Access

The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine

IEIan Escudero DGDieter Gniel SBShibadas Biswal

Key Points

The review aims to outline the critical decisions made during the development of the TAK-003 dengue vaccine.
Overview of vaccine composition decisions
Assessment of safety factors for live-attenuated vaccines
Discussion of dosing schedules
Immunogenicity assessments
Design considerations for the phase 3 efficacy study
TAK-003 demonstrates improved safety profiles for live-attenuated vaccines.
The vaccine composition supports enhanced immunogenicity against dengue.
Phase 3 study reveals critical efficacy metrics for informing vaccination strategies.

Abstract

Abstract The approved, live-attenuated tetravalent dengue vaccine TAK-003 has undergone extensive preclinical and clinical assessment. This review provides an overview of the rationale for some key decisions made during TAK-003 development. These include decisions around vaccine composition, assessment of factors that may be associated with the safety of live-attenuated viral vaccines, dosing schedule, immunogenicity assessments, and design of the pivotal phase 3 efficacy study.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper